[Modern TARE 2023 - from Palliative Care to a Curative Treatment Alternative]

Overview

Journal Nuklearmedizin

Publisher Thieme

Specialty Nuclear Medicine

Date 2024 Jul 16

PMID 39013456

Authors

Bernhard Gebauer

Federico Collettini

Christian Helmut Pfob

Constantin Lapa

Affiliations

Soon will be listed here.

Abstract

Selective internal radiotherapy (SIRT) or transarterial radioembolisation (TARE) is an alternative treatment for hepatocellular carcinoma (HCC) or hepatic metastatic colorectal carcinoma (mCRC) and is now anchored in many guidelines. The article summarises the current guidelines on SIRT/TARE in HCC and mCRC.

References

Gibbs P, Heinemann V, Sharma N, Taieb J, Ricke J, Peeters M . Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. Clin Colorectal Cancer. 2018; 17(4):e617-e629. DOI: 10.1016/j.clcc.2018.06.001. View

Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J . Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010; 28(23):3687-94. DOI: 10.1200/JCO.2010.28.5643. View

Palmer D, Hawkins N, Vilgrain V, Pereira H, Chatellier G, Ross P . Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study. Future Oncol. 2019; 16(1):4315-4325. DOI: 10.2217/fon-2019-0658. View

Jeyarajah D, Doyle M, Espat N, Hansen P, Iannitti D, Kim J . Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm. J Gastrointest Oncol. 2020; 11(2):443-460. PMC: 7212103. DOI: 10.21037/jgo.2020.01.09. View

Ludwig J, Zhang D, Xing M, Kim H . Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus Y-radioembolization for hepatocellular carcinoma. Eur Radiol. 2016; 27(5):2031-2041. DOI: 10.1007/s00330-016-4548-3. View

Van Cutsem E, Cervantes A, Adam R, Sobrero A, van Krieken J, Aderka D . ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27(8):1386-422. DOI: 10.1093/annonc/mdw235. View

Abdel-Rahman O, Elsayed Z . Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2020; 1:CD011313. PMC: 6984619. DOI: 10.1002/14651858.CD011313.pub3. View

Ettorre G, Levi Sandri G, Laurenzi A, Colasanti M, Meniconi R, Lionetti R . Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. World J Surg. 2016; 41(1):241-249. DOI: 10.1007/s00268-016-3682-z. View

Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, De Baere T . Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2020; 6(1):17-29. DOI: 10.1016/S2468-1253(20)30290-9. View

10.

Yang J, Wang J, Zhou H, Zhou Y, Wang Y, Jin H . Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial. Endoscopy. 2018; 50(8):751-760. DOI: 10.1055/s-0043-124870. View

11.

Mulcahy M, Mahvash A, Pracht M, Montazeri A, Bandula S, Martin 2nd R . Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. J Clin Oncol. 2021; 39(35):3897-3907. PMC: 8660005. DOI: 10.1200/JCO.21.01839. View

12.

Mikell J, Dewaraja Y, Owen D . Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models. Semin Radiat Oncol. 2019; 30(1):68-76. PMC: 8063594. DOI: 10.1016/j.semradonc.2019.08.005. View

13.

Garlipp B, Gibbs P, Van Hazel G, Jeyarajah R, Martin R, Bruns C . Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial. Br J Surg. 2019; 106(13):1837-1846. PMC: 6899564. DOI: 10.1002/bjs.11283. View

14.

Miller F, Vendrami C, Gabr A, Horowitz J, Kelahan L, Riaz A . Evolution of Radioembolization in Treatment of Hepatocellular Carcinoma: A Pictorial Review. Radiographics. 2021; 41(6):1802-1818. DOI: 10.1148/rg.2021210014. View

15.

Chapman W, Garcia-Aroz S, Vachharajani N, Fowler K, Saad N, Lin Y . Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions. J Am Coll Surg. 2017; 224(4):610-621. DOI: 10.1016/j.jamcollsurg.2016.12.020. View

16.

. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56(4):908-43. DOI: 10.1016/j.jhep.2011.12.001. View

17.

Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A . BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2021; 76(3):681-693. PMC: 8866082. DOI: 10.1016/j.jhep.2021.11.018. View

18.

dAbadie P, Walrand S, Lhommel R, Hesse M, Borbath I, Jamar F . Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria. Curr Oncol. 2022; 29(4):2422-2434. PMC: 9024927. DOI: 10.3390/curroncol29040196. View

19.

Hermann A, Dieudonne A, Ronot M, Sanchez M, Pereira H, Chatellier G . Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with Y in the SARAH Study. Radiology. 2020; 296(3):673-684. DOI: 10.1148/radiol.2020191606. View

20.

Van Hazel G, Heinemann V, Sharma N, Findlay M, Ricke J, Peeters M . SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2016; 34(15):1723-31. DOI: 10.1200/JCO.2015.66.1181. View